Precision Therapeutics, Inc. Engages Richard Gabriel to Drive Business Development Strategy for its TumorGenesis Subsidiary

Richard Gabriel, BS, MBA is a board member of Precision Therapeutics and spearheaded the licensing of new technologies for 3D cell culturing from 48 Hour Discovery, SyntArray and CellBridge MINNEAPOLIS, April 09, 2018 (GLOBE NEWSWIRE)  Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has engaged Richard Gabriel as a consultant to lead the external business development strategy for TumorGenesis, Inc., its The post Precision Therapeutics, Inc. Engages Richard Gabriel to Drive Business Development Strategy for its TumorGenesis Subsidiary appeared first on Public Wire.
http://bit.ly/2v5Bvuc